Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604214 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,696
- Enrollment target
NCT00604214 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,696 participants.
The verdict
NCT00604214, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,696 participants
- Enrollment target
Study Summary
The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated) treatment provides significant mortality reduction improvement in patients with septic shock compared with placebo treatment in patients receiving the current standard of care for septic shock. This study will also assess the effectiveness of drotrecogin alfa (activated) in reducing 28-day mortality in patients with septic shock and concomitant severe protein C deficiency.
Interventions
- DRUG Placebo
- DRUG Drotrecogin alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,696 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00604214
The ClinicalTrials.gov registry entry for NCT00604214 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,696 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00604214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00604214 about?
NCT00604214 is a clinical study titled "Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock". The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated) treatment provides significant mortality reduction improvement in patients with septic shock compared with placebo treatment in patients receiving the current standard of care for septic shock. This study wi...
What is the current status of trial NCT00604214?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,696 participants. The study started on 2008-03. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00604214?
The interventions under investigation include: Placebo (DRUG), Drotrecogin alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT00604214?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.